Literature DB >> 8816970

Antigen based therapies to prevent diabetes in NOD mice.

V K Ramiya1, X Z Shang, P G Pharis, C H Wasserfall, T V Stabler, A B Muir, D A Schatz, N K Maclaren.   

Abstract

Interventional approaches that have been successful in delaying insulin-dependent diabetes mellitus (IDDM) using antigen-based immunotherapies include parenteral immunization. It has potential for clinical application provided that effective adjuvants suitable for human use can be found. We have previously shown that immunization with insulin and insulin B chain but not A chain in incomplete Freund's adjuvant (IFA) prevented diabetes by reducing IFN-gamma mRNA in the insulitis lesions. In this paper we show that the insulin B chain peptide (p9-23) contain the most protective epitope. Immunization with selected GAD peptides was ineffective. Immunization with B chain but not A chain using alum as adjuvant delayed diabetes onset (P = 0.012), whereas administration of alum alone was not protective. When Diphtheria-Tetanus toxoid-Acellular Pertussis (DTP) vaccine was used as the adjuvant vehicle, DTP itself induced significant protection (P < 0.003) which was associated with a Th2-like cytokine producing insulitis profile, IL-4 driven IgG1 antibody responses to insulin, GAD in the periphery and an augmentation of the autoimmune response to GAD. The anti-diabetic effect of DTP was enhanced when given with insulin B chain. These results encourage consideration of an approach using alum/DTP and insulin B chain immunization in clinical trials.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8816970     DOI: 10.1006/jaut.1996.0047

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  9 in total

Review 1.  Immunisation and type 1 diabetes mellitus: is there a link?

Authors:  M Hiltunen; M Lönnrot; H Hyöty
Journal:  Drug Saf       Date:  1999-03       Impact factor: 5.606

2.  Acellular Bordetella pertussis vaccine enhances mucosal interleukin-10 production, induces apoptosis of activated Th1 cells and attenuates colitis in Galphai2-deficient mice.

Authors:  L Ohman; R Willén; O H Hultgren; E Hultgren Hörnquist
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

3.  Genetic fusion of human insulin B-chain to the B-subunit of cholera toxin enhances in vitro antigen presentation and induction of bystander suppression in vivo.

Authors:  Hamid Sadeghi; Søren Bregenholt; Dale Wegmann; Jacob S Petersen; Jan Holmgren; Michael Lebens
Journal:  Immunology       Date:  2002-06       Impact factor: 7.397

4.  Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy.

Authors:  Tihamer Orban; Klara Farkas; Heyam Jalahej; Janos Kis; Andras Treszl; Ben Falk; Helena Reijonen; Joseph Wolfsdorf; Alyne Ricker; Jeffrey B Matthews; Nadio Tchao; Peter Sayre; Pete Bianchine
Journal:  J Autoimmun       Date:  2010-06       Impact factor: 7.094

Review 5.  Do bugs control our fate? The influence of the microbiome on autoimmunity.

Authors:  Irene Fung; Jackie P-D Garrett; Anupama Shahane; Mildred Kwan
Journal:  Curr Allergy Asthma Rep       Date:  2012-12       Impact factor: 4.806

6.  Single-chain insulins as receptor agonists.

Authors:  Gautam Rajpal; Ming Liu; Yi Zhang; Peter Arvan
Journal:  Mol Endocrinol       Date:  2009-02-19

7.  The incidence of type-1 diabetes in NOD mice is modulated by restricted flora not germ-free conditions.

Authors:  Cecile King; Nora Sarvetnick
Journal:  PLoS One       Date:  2011-02-25       Impact factor: 3.240

8.  Protection against autoimmune diabetes by silkworm-produced GFP-tagged CTB-insulin fusion protein.

Authors:  Qiaohong Meng; Wenfeng Wang; Xiaowen Shi; Yongfeng Jin; Yaozhou Zhang
Journal:  Clin Dev Immunol       Date:  2011-06-06

9.  Severe anaphylactic reactions to glutamic acid decarboxylase (GAD) self peptides in NOD mice that spontaneously develop autoimmune type 1 diabetes mellitus.

Authors:  Rosetta Pedotti; Maija Sanna; Mindy Tsai; Jason DeVoss; Lawrence Steinman; Hugh McDevitt; Stephen J Galli
Journal:  BMC Immunol       Date:  2003-02-22       Impact factor: 3.615

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.